evrazkarЕвразийский Кардиологический ЖурналEurasian heart journal2225-16852305-0748Евразийская ассоциация кардиологов10.38109/2225-1685-2017-4-114-120evrazkar-264Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSДАБИГАТРАНА ЭТЕКСИЛАТ У ПОЖИЛЫХ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ: ЧТО НОВОГО?DABIGATRAN ETEXILATE IN ELDERL Y PATIENTS WITH ATRIAL FIBRILLATION: WHATS NEW?ТкачёваО. Н.TkachevaO. N.

Д.м.н., профессор, главный внештатный гериатр Минздрава России, директор

129226, г. Москва, ул. 1-ая Леонова, д. 16

тел. +7 (499) 187-64-67

MD, professor, chief geriatrist of the Ministry of Health of Russia, director 

129226, Moscow, 1-st Leonova street, 16

tel. +7 (499) 187-64-67

clinicarnimu@mail.ruВоробьёваН. М.VorobyevaN. M.

Д.м.н., старший научный сотрудник лаборатории сердечно-сосудистого старения 

129226, г. Москва, ул.1-ая Леонова, д.16

тел. +7 (499) 187-64-67

MD, Ph.D, Laboratory of Cardiovascular Aging

129226, Moscow, 1-st Leonova street, 16

tel. +7 (499) 187-64-67

natalyavorobjeva@mail.ruРоссийский геронтологический научно-клинический центрРоссияRussian Gerontological Scientific and Clinical CenterRussian Federation20173012201704114120Copyright © Ткачёва О.Н., Воробьёва Н.М., 20172017Ткачёва О.Н., Воробьёва Н.М.Tkacheva O.N., Vorobyeva N.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.heartj.asia/jour/article/view/264

В статье обсуждаются вопросы профилактики инсульта у пожилых пациентов с фибрилляцией предсердий. Обсуждаются принципы выбора антикоагулянтной терапии в данной группе пациентов. Подчеркивается значимость профиля безопасности выбираемого антикоагулянта с учетом высокой распространенности сопутствующей патологии у пожилых пациентов. Детально разбирается профиль эффективности и безопасности дабигатрана этексилата, продемонстриро ванный в рандомизированных клинических исследованиях и реальной клинической практике. На основании обсуждаемых данных авторы делают вывод о то, что дабигатран может рассматриваться предпочтительным антикоагулянтом для длительного лечения у пожилых пациентов с фибрилляцией предсердий.

The article discusses stroke prevention in elderly patients with atrial fibrillation. The principles of choosing anticoagulant therapy in this group of patients are discussed. The importance of the safety profile of the selected anticoagulant is emphasized considering the high prevalence of comorbidities in elderly patients. The efficacy and profile of dabigatran etexilate demonstrated in randomized clinical trials and in real clinical practice is analyzed in detail. Based on the data discussed, the authors are coming to conclusion that dabigatran can be considered the preferred anticoagulant for long-term treatment in elderly patients with atrial fibrillation.

дабигатрана этексилатантикоагулянтНОАКишемический инсультпожилые пациентыфибрилляция предсердийdabigatran etexilateanticoagulantNOACstrokeelderly patientsatrial fibrillationReferencesSchnabel R.B., Yin X, Gona P. et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015; 386:154-162.Schnabel R.B., Yin X, Gona P. et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015; 386:154-162.Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147:1561-1564.Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147:1561-1564.Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.Lauw M.N., Eikelboom J.W., Coppens M. et al. Effects of dabigatran according to age in atrial fibrillation. Heart 2017; 103:1015-1023.Lauw M.N., Eikelboom J.W., Coppens M. et al. Effects of dabigatran according to age in atrial fibrillation. Heart 2017; 103:1015-1023.Eikelboom J.W., Wallentin L., Connolly S.J. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.Eikelboom J.W., Wallentin L., Connolly S.J. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.Lip G.Y.H., Clemens A, Noack H. et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111:933-942.Lip G.Y.H., Clemens A, Noack H. et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111:933-942.Andreotti F., Rocca B., Husted S. et al., on behalf of the ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; 36: 3238-3249.Andreotti F., Rocca B., Husted S. et al., on behalf of the ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; 36: 3238-3249.Graham D.J., Reichman M.E., Wernecke M. et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation 2015; 131: 157164. Epub 2014 Oct 30.Graham D.J., Reichman M.E., Wernecke M. et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation 2015; 131: 157164. Epub 2014 Oct 30.Graham D.J., Reichman M.E., Wernecke M. et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016; 176:1662-1671.Graham D.J., Reichman M.E., Wernecke M. et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016; 176:1662-1671.Hernandez I., Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs 2017; 17:37-47. Epub 2016 Sep 14.Hernandez I., Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs 2017; 17:37-47. Epub 2016 Sep 14.Nielsen P.B., Skjoth F., Sogaard M. et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510.Nielsen P.B., Skjoth F., Sogaard M. et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510.

The authors declare that there are no conflicts of interest present.